Anocca has Dosed First Patients with Precision TCR-T Cell Therapy Targeting Mutant KRAS in Pancreatic Cancer

Contributed by: Business Wire

Tags

Biotechnology

Technology

Health

Pharmaceutical

Oncology

Health Technology

Research

Software

Genetics

Science

Clinical Trials

HEALTH

More Like This

Anocca Raises SEK 440 Million to Advance Clinical Trial Targeting Pancreatic Cancer

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025

Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025

PR Newswire associated0

Experimental Drug Development Centre Granted U.S. FDA Fast Track Designation for Antibody-Drug Conjugate EBC-129 to Treat Pancreatic Ductal Adenocarcinoma

PR Newswire associated0

Experimental Drug Development Centre Announces the Presentation of Updated Data from the Phase 1 Study of Antibody-Drug Conjugate EBC-129 at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)

PR Newswire associated0

AvenCell Announces First Patient Dosed in a Phase IA Study with lead product candidate AVC-201, a Novel Allogeneic CD123-Directed Switchable CAR-T Investigational Therapy for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia and other CD123 Hematological Malignancies